Does Barry E. Greene have related-party ties or family relationships at Dyne Therapeutics (DYN)?

The company states there are no arrangements or understandings with other persons regarding his election and no family relationships with directors or executive officers. It also reports no transactions requiring disclosure under Item 404(a) of Regulation S-K.

Dyne Therapeutics adds Barry Greene to board

Dyne Therapeutics appointed Barry E. Greene to its Board of Directors as a Class I director, with a term running until the 2027 annual meeting and continuation until a successor is elected or earlier departure.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Dyne Therapeutics appointed Barry E. Greene to its Board of Directors as a Class I director, with a term running until the 2027 annual meeting and continuation until a successor is elected or earlier departure.

The Board determined that Greene is an independent director under Nasdaq rules. Upon joining, he received a stock option for 57,463 shares at an exercise price of $20.87 per share, vesting in equal monthly installments over three years, with full acceleration upon a change in control. He will also receive $45,000 in annual cash compensation, additional annual equity grants under the non-employee director compensation program, and reimbursement of reasonable expenses related to Board meetings.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Key Figures

Director stock option grant: 57,463 shares Option exercise price: $20.87 per share Vesting period: 3 years +1 more

4 metrics

Director stock option grant 57,463 shares Option to purchase common stock granted upon Board election

Option exercise price $20.87 per share Closing price of common stock on grant date

Vesting period 3 years Option vests in equal monthly installments over three years

Annual cash retainer $45,000 Yearly cash compensation as a member of the Board

Key Terms

independent director, 2020 Stock Incentive Plan, change in control, indemnification agreement

4 terms

independent director financial

"The Board has determined that Mr. Greene is an “independent” director under the Nasdaq Stock Market rules."

An independent director is a member of a company's board of directors who is not involved in the company's day-to-day operations and has no significant relationships with the company that could influence their judgment. Their role is to provide unbiased oversight and ensure the company is managed in the best interests of all shareholders. This helps build trust and confidence among investors by promoting transparency and accountability.

2020 Stock Incentive Plan financial

"he received, under the Company’s 2020 Stock Incentive Plan, an option to purchase 57,463 shares"

change in control financial

"In the event of a change in control of the Company, the vesting schedule of the option will accelerate in full."

A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.

indemnification agreement financial

"Mr. Greene will enter into the Company’s standard form of indemnification agreement."

An indemnification agreement is a contract in which one party promises to cover losses, costs, or legal claims that another party might face, acting like a tailored safety net or private insurance policy. For investors, it matters because such agreements shift potential financial risk away from a company or its officers and onto the indemnifier, which can affect a company’s future liabilities, cash flow and how risky the investment appears during deal-making or litigation.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Dyne Therapeutics (DYN) announce about its Board of Directors?

Dyne Therapeutics added Barry E. Greene as a Class I director to its Board. He will serve until the 2027 annual meeting and continue until a successor is elected or he departs earlier, strengthening the company’s governance structure with another independent board member.

Is Barry E. Greene considered an independent director at Dyne Therapeutics (DYN)?

Yes, the Board determined that Barry E. Greene qualifies as an independent director under Nasdaq rules. This designation means he meets specific criteria regarding relationships and affiliations, supporting objective oversight of management and alignment with recognized corporate governance standards.

What equity compensation will Barry E. Greene receive from Dyne Therapeutics (DYN)?

Upon election, Barry E. Greene received an option to purchase 57,463 Dyne Therapeutics common shares at $20.87 per share. The option vests in equal monthly installments over three years and fully accelerates if there is a change in control of the company.

What cash compensation will Barry E. Greene earn as a Dyne Therapeutics (DYN) director?

As a Board member, Barry E. Greene will receive annual cash compensation of $45,000. He will also receive annual equity grants under the non-employee director compensation program and reimbursement for reasonable travel and out-of-pocket expenses related to attending Board meetings.

What happens to Barry E. Greene’s Dyne Therapeutics (DYN) stock options if there is a change in control?

If Dyne Therapeutics undergoes a change in control, the vesting of Barry E. Greene’s stock option accelerates in full. This means all unvested option shares would become fully exercisable at that time, instead of continuing on the monthly vesting schedule.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/22/2026 - 04:15 PM EDT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): June 22, 2026

Dyne Therapeutics, Inc.

(Exact Name of Registrant as Specified in Charter)


Delaware	001-39509	36-4883909
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

1560 Trapelo Road Waltham, Massachusetts		02451
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (781) 786-8230

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading symbol(s)	Name of each exchange on which registered
Common stock, $0.0001 par value per share	DYN	Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On June 22, 2026, the Board of Directors (the “Board”) of Dyne Therapeutics, Inc. (the “Company”), upon recommendation from the Nominating and Corporate Governance Committee of the Board, elected Barry E. Greene as a Class I director to serve on the Board until the Company’s 2027 Annual Meeting of Stockholders and until his successor has been duly elected and qualified or until his earlier death, resignation or removal. Mr. Greene has not been appointed to serve on any committees of the Board. The Board has determined that Mr. Greene is an “independent” director under the Nasdaq Stock Market rules.

Mr. Greene shall be entitled to receive compensation under the Company’s non-employee director compensation program. In accordance with this program, upon his election to the Board, Mr. Greene received, under the Company’s 2020 Stock Incentive Plan, an option to purchase 57,463 shares of the Company’s common stock at an exercise price equal to $20.87 per share, the closing price of the Company’s common stock on the date of grant, which option will vest and become exercisable in equal monthly installments over the next three years, subject to his continued service. In the event of a change in control of the Company, the vesting schedule of the option will accelerate in full. In addition, Mr. Greene will receive annual cash compensation of $45,000 as a member of the Board, annual equity grants in accordance with the non-employee director compensation program and reimbursement for reasonable travel and out-of-pocket expenses incurred in connection with attending Board meetings.

There are no arrangements or understandings between Mr. Greene and any other persons pursuant to which he was elected as a director. Mr. Greene does not have any family relationships with any of the Company’s directors or executive officers. There are no transactions and no proposed transactions between Mr. Greene and the Company that would be required to be disclosed pursuant to Item 404(a) of Regulation S-K.

Mr. Greene will enter into the Company’s standard form of indemnification agreement. The form of the indemnification agreement was filed as Exhibit 10.10 to the Company’s Registration Statement on Form S-1 filed with the U.S. Securities and Exchange Commission on August 25, 2020.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.



	DYNE THERAPEUTICS, INC.

Date: June 22, 2026	By:	/s/ John G. Cox
		Name:	John G. Cox
		Title:	President and Chief Executive Officer

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

1 document